Search Results for "Pregnancy"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Pregnancy. Results 941 to 950 of 974 total matches.

Plenvu - A Low-Volume PEG-Based Colonoscopy Preparation

   
The Medical Letter on Drugs and Therapeutics • Jan 28, 2019  (Issue 1564)
before use of the drug in patients with phenylketonuria. PREGNANCY — There are no adequate data ...
The FDA has approved Plenvu (Salix), a polyethylene glycol (PEG)-containing oral powder for reconstitution, for colon cleansing prior to colonoscopy in adults. Plenvu is the first PEG-containing colonoscopy preparation that requires only 1 L of water for dissolution and ingestion of 1 L of clear fluid in addition.
Med Lett Drugs Ther. 2019 Jan 28;61(1564):11-4 |  Show IntroductionHide Introduction

Romosozumab (Evenity) for Postmenopausal Osteoporosis

   
The Medical Letter on Drugs and Therapeutics • Jun 03, 2019  (Issue 1573)
they reduce the ef ficacy of the drug is unknown. PREGNANCY — Administration of romosozumab to pregnant ...
The FDA has approved romosozumab-aqqg (Evenity – Amgen), a sclerostin inhibitor, for once-monthly subcutaneous (SC) treatment of osteoporosis in postmenopausal women who are at high risk for fracture (history of osteoporotic fracture or multiple risk factors for fracture) or who have failed or cannot tolerate other drugs for this indication. Romosozumab is the first sclerostin inhibitor to be approved in the US and the third drug for treatment of postmenopausal osteoporosis that stimulates bone formation; the parathyroid hormone (PTH) receptor agonists abaloparatide (Tymlos) and...
Med Lett Drugs Ther. 2019 Jun 3;61(1573):83-6 |  Show IntroductionHide Introduction

Risankizumab (Skyrizi) for Psoriasis

   
The Medical Letter on Drugs and Therapeutics • Jun 03, 2019  (Issue 1573)
in approximately 1% of patients. PREGNANCY AND LACTATION — Human IgG antibodies cross the placenta (especially ...
The FDA has approved the interleukin (IL)-23 antagonist risankizumab-rzaa (Skyrizi – Abbvie) for treatment of moderate to severe plaque psoriasis in adults. Risankizumab is the third IL-23 antagonist to be approved for this indication; guselkumab (Tremfya) and tildrakizumab (Ilumya) were approved earlier.
Med Lett Drugs Ther. 2019 Jun 3;61(1573):81-3 |  Show IntroductionHide Introduction

IV Amisulpride (Barhemsys) for Postoperative Nausea and Vomiting

   
The Medical Letter on Drugs and Therapeutics • Dec 28, 2020  (Issue 1614)
is recommended when amisulpride is used with other drugs that also prolong the QT interval.8 PREGNANCY ...
The FDA has approved IV amisulpride (Barhemsys – Acacia), a selective dopamine-2 and -3 (D2/D3) receptor antagonist, for prevention and treatment of postoperative nausea and vomiting (PONV) in adults. It is the first antiemetic to be approved for rescue treatment of PONV in patients who have symptoms despite receiving antiemetic prophylaxis. Oral formulations of amisulpride are available in Europe for treatment of schizophrenia and acute psychotic episodes.
Med Lett Drugs Ther. 2020 Dec 28;62(1614):205-8 |  Show IntroductionHide Introduction

Two New Pneumococcal Vaccines - Prevnar 20 and Vaxneuvance

   
The Medical Letter on Drugs and Therapeutics • Nov 29, 2021  (Issue 1638)
with a quadrivalent inactivated influenza vaccine. PREGNANCY AND LACTATION — There are no data on the use of PCV20 ...
The FDA has licensed two new pneumococcal conjugate vaccines (PCVs) for prevention of invasive pneumococcal disease in adults: Prevnar 20 (PCV20; Pfizer), which contains antigens from 20 serotypes of pneumococcus, and Vaxneuvance (PCV15; Merck), which contains antigens from 15 serotypes. Two other pneumococcal vaccines are available in the US: Prevnar 13 (PCV13; Pfizer), a 13-valent conjugate vaccine licensed for use in persons ≥6 weeks old, and Pneumovax 23 (PPSV23; Merck), a 23-valent pneumococcal polysaccharide vaccine licensed for use in persons ≥2 years...
Med Lett Drugs Ther. 2021 Nov 29;63(1638):188-90 |  Show IntroductionHide Introduction

Treatment of Menopausal Vasomotor Symptoms

   
The Medical Letter on Drugs and Therapeutics • Dec 06, 2004  (Issue 1197)
of pregnancy prevention. 10,11 Progestins alone are somewhat effective for treatment of hot flashes in women ...
Estrogen is the most effective treatment for menopausal vasomotor symptoms (hot flashes), but the Women's Health Initiative study found that women who took estrogen plus a progestin for more than 5 years were at increased risk for myocardial infarction, stroke, pulmonary emboli, deep vein thrombosis, breast cancer, and possibly dementia. Are there effective alternatives?
Med Lett Drugs Ther. 2004 Dec 6;46(1197):98-9 |  Show IntroductionHide Introduction

Arformoterol (Brovana) for COPD

   
The Medical Letter on Drugs and Therapeutics • Jul 02, 2007  (Issue 1264)
in pregnancy (teratogenic in animals). The labels of long-acting beta 2 -agonists warn that their use ...
Arformoterol tartrate (Brovana - Sepracor), a singleisomer, long-acting beta2-agonist, has been approved by the FDA as an inhalation solution for nebulization for treatment of bronchoconstriction pulmonary disease (COPD). Arformoterol is the (R,R)-enantiomer of formoterol (Foradil), which is available as a powder for inhalation and was recently also approved as a solution for nebulization (Perforomist - Dey; available fall 2007)
Med Lett Drugs Ther. 2007 Jul 2;49(1264):53-5 |  Show IntroductionHide Introduction

Vigabatrin (Sabril) for Epilepsy

   
The Medical Letter on Drugs and Therapeutics • Feb 22, 2010  (Issue 1332)
be ruled out) for use in pregnancy. DRUG INTERACTIONS — Vigabatrin can lower serum concentrations ...
The FDA has approved vigabatrin (vye gá ba trin; Sabril – Lundbeck) for oral use as add-on therapy for complex partial seizures in adults who are refractory to several antiepileptic drugs and as monotherapy for infantile spasms. Vigabatrin has been available in other countries for many years. Because of its potential for retinal toxicity, it will be available in the US only through a restricted distribution program called SHARE (Support, Help and Resources for Epilepsy). Prescribers and pharmacists distributing the drug must register, and patients must undergo visual field testing.
Med Lett Drugs Ther. 2010 Feb 22;52(1332):14-6 |  Show IntroductionHide Introduction

Saxagliptin (Onglyza) for Type 2 Diabetes

   
The Medical Letter on Drugs and Therapeutics • Nov 02, 2009  (Issue 1324)
in humans) for use during pregnancy. DRUG INTERACTIONS — Saxagliptin is metabolized to an active ...
Saxagliptin (Onglyza - Bristol-Myers Squibb), the second oral dipeptidyl peptidase-4 (DPP-4) inhibitor to be marketed in the US, has been approved by the FDA for treatment of adults with type 2 diabetes.
Med Lett Drugs Ther. 2009 Nov 2;51(1324):85-6 |  Show IntroductionHide Introduction

Elbasvir/Grazoprevir (Zepatier) for Hepatitis C

   
The Medical Letter on Drugs and Therapeutics • Feb 29, 2016  (Issue 1489)
with moderate or severe hepatic impairment. PREGNANCY — Use of elbasvir/grazoprevir in pregnant women ...
The FDA has approved Zepatier (Merck), a fixed-dose combination of two direct-acting antiviral agents — elbasvir, an NS5A inhibitor, and grazoprevir, an NS3/4A protease inhibitor — for oral treatment of chronic hepatitis C virus (HCV) genotype 1 or 4 infection.
Med Lett Drugs Ther. 2016 Feb 29;58(1489):25-7 |  Show IntroductionHide Introduction